Head-to-Head trial: new drug challenges leading lung cancer treatment
NCT ID NCT07362459
Summary
This study aims to see if a new drug called SCTB14 works better than the standard drug pembrolizumab (Keytruda) for people with a specific type of advanced lung cancer. It will involve 246 adults who have not yet received treatment for their cancer. The main goal is to see if SCTB14 can keep the cancer from getting worse for a longer time than the current standard.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.